HH胶囊体内外抗乙肝病毒作用及其部分作用机制研究
|
摘要
乙型肝炎病毒(HBV)感染呈世界性流行,据世界卫生组织报道,全球约20亿人曾感染过HBV,其中3.5亿人为慢性HBV感染者,每年约有100万人死于HBV感染所致的肝衰竭、肝硬化和原发性肝细胞癌。我国属HBV感染高流行区,约有1.2亿病毒携带者,3000万例慢性乙型肝炎患者,每年死于肝炎及其并发症的患者达数十万人,我国HBV感染的直接医疗费用每年约数百亿元。可见HBV感染不仅已经成为严重影响人类健康的医学问题,而且也已经成为加重社会经济负担的社会问题,积极开展防治慢性乙型肝炎研究有重要现实意义,积极开发理想的抗HBV的药物是病毒性肝炎研究领域的热点。
目的：研究HH胶囊体内外抗乙型肝炎病毒作用及其部分作用机制。
方法：
1.将HepG2.2.15随机分组为空白对照组、DMSO组(0.1%)、不同浓度拉米夫定组(300、200、100μg/ml)、不同浓度HH胶囊组(5mg/ml、2.5mg/ml、1.25mg/ml、625μg/ml、312μg/ml、156μg/ml、78μg/ml、39μg/ml、20μg/ml、10μg/ml),分别给予相应的培养液,2天换液一次,分别在第2、4、6天时,用CCK-8检测药物细胞毒性,以找到最大无毒浓度,酶联免疫法(ELISA)检测乙肝病毒表面抗原(HBsAg)和乙肝病毒e抗原(HBeAg),荧光定量聚合酶链反应法(FQ-PCR)检测HBV脱氧核糖核酸(HBVDNA)。
2.采用鸭HBV血清制备鸭乙肝模型,随机分为模型组、拉米夫定组(100mg/kg·d)和高(10g/kg·d)、中(5g/kg·d)、低(2.5g/kg·d)剂量HH胶囊组,分别给与相应治疗后,分别在第10、13天时,采用ELISA检测血清中鸭HBV表面抗原(DHBsAg),FQ-PCR检测血清中鸭HBV脱氧核糖核酸(DHBVDNA).
3.将HepG2.2.15随机分组为DMSO组和高(312μg/ml)、低(78μg/m)剂量HH胶囊组,分别给予相应的培养液,2天换液一次,第6天时,FQ-PCR法检测细胞内信号转导和转录活化因子(STAT1)、STAT2、干扰素刺激基因因子3(ISGF3)、2′5′-寡腺苷酸合成酶(2′5′-OAS)、RAN依赖蛋白激酶(PKR) mRNA水平,Western Bloting方法检测细胞内OAS、PKR蛋白水平。
结果：体外实验表明HH胶囊可以不同程度降低细胞外HBsAg、HBeAg、HBV DNA及细胞内HBV DNA,此作用具有时间和药物浓度依赖性。HH胶囊可以增加细胞内STAT1、STAT2、ISGF3、OAS、PKR的mRNA水平,增强OAS、PKR蛋白水平。体内实验表明HH胶囊可以不同程度降低血清DHBsAg、DHBVDNA,停药后未见病毒复发。
结论：HH胶囊体内外均具有抗HBV作用,推测可能与调控JAK-STAT信号通路有关。
Hepatitis B Virus (HBV) infection was prevalent worldwide, according to the World Health Organization reporting, about 20 million people worldwide have been infected with HBV, of which 350 million people live with chronic HBV infection, about one million people died each year due to liver failure, cirrhosis and hepatocellular carcinoma with HBV infection. China is a high endemic area of HBV infection, about 120 million people are carriers of hepatitis B virus, of which about 30 million people were chronic hepatitis B patients, up to hundreds of thousands of patients died of hepatitis B and its complications each year,HBV infection leads to direct medical costs of 10 billion yuan each year. So HBV infection not only has become a serious medical problem affecting human health, but also has become a heavier economic burden on the social issues, so being active in prevention and treatment of chronic hepatitis B is important, Actively developing ideal anti-HBV drugs is the focus in the field of viral hepatitis research.
Objective:To study the anti-hepatitis B virus effect of HH Capsules and its part of the mechanism in vivo and in vitro.
Methods:
1. HepG2.2.15 were randomized to the control group, the DMSO group (0.1%), the lamivudine groups with different concentration (300、200、100μg/ml) and the HH capsule groups with different concentration (5mg/ml、2.5mg/ml、1.25mg/ml、625μg/ml、312μg/ml、156μg/ml、78μg/ml、39μg/ml、20μg/ml、10μg/ml), All groups were given the appropriate culture medium, medium was changed once every 2 days, at the time of the day 2,4,6, CCK-8 was used to detect drug toxicity to find the maximum non-toxic concentration, Enzyme Linked Immunosorbent Assay (ELISA) was usede to detect hepatitis B virus surface antigen (HBsAg) and hepatitis B virus e antigen (HBeAg),Fluorescence Quantitative Polymerase Chain Reaction (FQ-PCR) was used to detect hepatitis B virus DNA (HBVDNA).
2. Duck hepatitis B model was preparaed by using Duck hepatitis B virus blood,Duck hepatitis B were randomly divided into the model group,the lamivudine group (100mg/kg-d)and the HH capsule groups with the high(10g/kg-d), medium (5g/kg-d) and low (2.5g/kg-d) doses respectively, after giving the appropriate treatment, at the time of the day 10, day 13, ELISA was usede to detect serum DHBsAg, FQ-PCR was used to detect serum DHBVDNA.
3. HepG2.2.15 were randomized to the DMSO group, HH capsule groups with High (312μg/ml) and low (78μg/ml) doses, All groups were given the appropriate culture medium, medium was changed once every 2 days, at the time of day 6, FQ-PCR was usede to detect the intracellular Signal Transducers and Activators of Transcription1 (STAT1), STAT2, IFN-stimulated gene factor 3(ISGF3),2' 5'-Oligoadenylate Synthetase(2'5'-OAS),RAN-dependent protein kinase (PKR) mRNA level, the intracellular protein of OAS, PKR was detected by Western Bloting.
Results:In vitro experiment,it shows that, to different degree, HH capsules could reduce the quantity of extracellular HBsAg, HBeAg, HBV DNA and the intracellular HBV DNA in a time and dose-dependent manner.and the HH capsule could increase the intracellular STAT1, STAT2, ISGF3, OAS, PKR mRNA level and enhance the OAS, PKR protein. In vivo experiment,it shows that the HH capsule could reduce the quantity of serum. DHBsAg and DHBV DNA,without virus rebounding after drug withdrawal.
Conclusion:HH Capsules has definite anti-HBV effect in vivo and in vitro,likely relating to regulating the JAK-STAT signaling pathway.
目的：研究HH胶囊体内外抗乙型肝炎病毒作用及其部分作用机制。
方法：
1.将HepG2.2.15随机分组为空白对照组、DMSO组(0.1%)、不同浓度拉米夫定组(300、200、100μg/ml)、不同浓度HH胶囊组(5mg/ml、2.5mg/ml、1.25mg/ml、625μg/ml、312μg/ml、156μg/ml、78μg/ml、39μg/ml、20μg/ml、10μg/ml),分别给予相应的培养液,2天换液一次,分别在第2、4、6天时,用CCK-8检测药物细胞毒性,以找到最大无毒浓度,酶联免疫法(ELISA)检测乙肝病毒表面抗原(HBsAg)和乙肝病毒e抗原(HBeAg),荧光定量聚合酶链反应法(FQ-PCR)检测HBV脱氧核糖核酸(HBVDNA)。
2.采用鸭HBV血清制备鸭乙肝模型,随机分为模型组、拉米夫定组(100mg/kg·d)和高(10g/kg·d)、中(5g/kg·d)、低(2.5g/kg·d)剂量HH胶囊组,分别给与相应治疗后,分别在第10、13天时,采用ELISA检测血清中鸭HBV表面抗原(DHBsAg),FQ-PCR检测血清中鸭HBV脱氧核糖核酸(DHBVDNA).
3.将HepG2.2.15随机分组为DMSO组和高(312μg/ml)、低(78μg/m)剂量HH胶囊组,分别给予相应的培养液,2天换液一次,第6天时,FQ-PCR法检测细胞内信号转导和转录活化因子(STAT1)、STAT2、干扰素刺激基因因子3(ISGF3)、2′5′-寡腺苷酸合成酶(2′5′-OAS)、RAN依赖蛋白激酶(PKR) mRNA水平,Western Bloting方法检测细胞内OAS、PKR蛋白水平。
结果：体外实验表明HH胶囊可以不同程度降低细胞外HBsAg、HBeAg、HBV DNA及细胞内HBV DNA,此作用具有时间和药物浓度依赖性。HH胶囊可以增加细胞内STAT1、STAT2、ISGF3、OAS、PKR的mRNA水平,增强OAS、PKR蛋白水平。体内实验表明HH胶囊可以不同程度降低血清DHBsAg、DHBVDNA,停药后未见病毒复发。
结论：HH胶囊体内外均具有抗HBV作用,推测可能与调控JAK-STAT信号通路有关。
Hepatitis B Virus (HBV) infection was prevalent worldwide, according to the World Health Organization reporting, about 20 million people worldwide have been infected with HBV, of which 350 million people live with chronic HBV infection, about one million people died each year due to liver failure, cirrhosis and hepatocellular carcinoma with HBV infection. China is a high endemic area of HBV infection, about 120 million people are carriers of hepatitis B virus, of which about 30 million people were chronic hepatitis B patients, up to hundreds of thousands of patients died of hepatitis B and its complications each year,HBV infection leads to direct medical costs of 10 billion yuan each year. So HBV infection not only has become a serious medical problem affecting human health, but also has become a heavier economic burden on the social issues, so being active in prevention and treatment of chronic hepatitis B is important, Actively developing ideal anti-HBV drugs is the focus in the field of viral hepatitis research.
Objective:To study the anti-hepatitis B virus effect of HH Capsules and its part of the mechanism in vivo and in vitro.
Methods:
1. HepG2.2.15 were randomized to the control group, the DMSO group (0.1%), the lamivudine groups with different concentration (300、200、100μg/ml) and the HH capsule groups with different concentration (5mg/ml、2.5mg/ml、1.25mg/ml、625μg/ml、312μg/ml、156μg/ml、78μg/ml、39μg/ml、20μg/ml、10μg/ml), All groups were given the appropriate culture medium, medium was changed once every 2 days, at the time of the day 2,4,6, CCK-8 was used to detect drug toxicity to find the maximum non-toxic concentration, Enzyme Linked Immunosorbent Assay (ELISA) was usede to detect hepatitis B virus surface antigen (HBsAg) and hepatitis B virus e antigen (HBeAg),Fluorescence Quantitative Polymerase Chain Reaction (FQ-PCR) was used to detect hepatitis B virus DNA (HBVDNA).
2. Duck hepatitis B model was preparaed by using Duck hepatitis B virus blood,Duck hepatitis B were randomly divided into the model group,the lamivudine group (100mg/kg-d)and the HH capsule groups with the high(10g/kg-d), medium (5g/kg-d) and low (2.5g/kg-d) doses respectively, after giving the appropriate treatment, at the time of the day 10, day 13, ELISA was usede to detect serum DHBsAg, FQ-PCR was used to detect serum DHBVDNA.
3. HepG2.2.15 were randomized to the DMSO group, HH capsule groups with High (312μg/ml) and low (78μg/ml) doses, All groups were given the appropriate culture medium, medium was changed once every 2 days, at the time of day 6, FQ-PCR was usede to detect the intracellular Signal Transducers and Activators of Transcription1 (STAT1), STAT2, IFN-stimulated gene factor 3(ISGF3),2' 5'-Oligoadenylate Synthetase(2'5'-OAS),RAN-dependent protein kinase (PKR) mRNA level, the intracellular protein of OAS, PKR was detected by Western Bloting.
Results:In vitro experiment,it shows that, to different degree, HH capsules could reduce the quantity of extracellular HBsAg, HBeAg, HBV DNA and the intracellular HBV DNA in a time and dose-dependent manner.and the HH capsule could increase the intracellular STAT1, STAT2, ISGF3, OAS, PKR mRNA level and enhance the OAS, PKR protein. In vivo experiment,it shows that the HH capsule could reduce the quantity of serum. DHBsAg and DHBV DNA,without virus rebounding after drug withdrawal.
Conclusion:HH Capsules has definite anti-HBV effect in vivo and in vitro,likely relating to regulating the JAK-STAT signaling pathway.
引文
[1]Ganem D,Prince AM.Hepatitis B virus infection natural history and clinical consequences [J].N Engl J Med,2004,350(3):1118-1129.
[2]石光,谢永富,刘秀颖,等.乙型肝炎经济负担的测算.中国初级卫生保健,2004,18(8)：18-19.
[3]Lotrich FE, Rabinovitz M, Gironda P, etal. Depression following pegylated interferon alpha:characteristics and vulnerability.J Psychosom Res,2007,63 (2):131-5.
[4]赵鸿,斯崇文,魏来,等.聚乙二醇化干扰素α-2b与干扰素α-2b治疗e抗原阳性慢性乙型肝炎的疗效和安全性的随机对照多中心研究.中华肝脏病杂志,2006,14(5)：323-326.
[5]Liaw YF, Leung N, Guan R.Asian-Pacific consensus statement on the management of chronic hepatitis B:anupdate [J].J Gastroenterol Hepatol,2003,18(3):239-245.
[6]张友祥,王灵台,陈建杰.中药补肾冲剂联合拉米夫定治疗慢性乙型肝炎88例[J].中西医结合肝病杂志,2003,13(2)：112-113.
[7]邱杰文,黄彩华,程红球,等.黄萱益肝散抗鸭乙型肝炎病毒及保护肝细胞的实验研究.现代中西医结合杂志,2008,17(14)：2128-2129.
[8]刘汉平,何金洋,梁波.扶正利湿活血复方对鸭胚肝细胞中鸭乙型肝炎病毒的抑制作用.时珍国医国药,2009,20(7)：1670-1672..
[9]刘丽丽,李常青,朱宇同,等.清肝排毒饮抗鸭乙型肝炎病毒的实验研究.中国热带医学,2007,7(2)：193-195.
[10]陈诗慧,莫运涛.疏肝健脾祛湿中药体内抗鸭乙型肝炎病毒的实验研究.中国医药导报,2008,5(13)：25-26.
[11]张永兴.神奇的抗病毒中草药[M].北京,中国中医药出版社,2004年第1版
[12]黄祝青,龚守军,孙永年,等.苦参素治疗慢性乙型肝炎疗效分析[J].肝脏,2002,7(1)：67-68.
[13]李宝剑,金丽琴,左江成.细脚拟青霉多糖抗乙型肝炎病毒的体外实验研.中药材,2007,30(2)：200-203.
[14]黄华,王歆君,杨巧丽,等.布亚胶囊抗HBV作用的实验研究.新疆中医药,2009,27(4)：3-5.
[15]湛孝东,王克霞,李朝品.蜗牛多糖体外抗乙型肝炎病毒作用研究.中国实验方剂学杂志.2008,14(3)：66-68.
[16]谢琼,谭德明,彭忠田,等.脱氧野尻霉素抑制乙型肝炎病毒复制的体外实验研究.中国感染控制杂志,2009,8(1)：3-6.
[17]李烨,王新华,卢梅生,等.混血穴位注射疗法治疗慢性乙型肝炎54例[J].中西医结合肝病杂志,2003,13(4)：200-201.
[18]徐金波,邹永芬.中药联合干扰素及胸腺因子D治疗慢性乙型肝炎53例观察[J].实用中药,2003,19(1)：26-27.
[19]蔡红兵,徐舒,李洪,等.逍遥丸联合阿德福韦治疗肝郁脾虚型慢性乙型肝炎疗效观察.湖南中医杂志,2007,23(5)：1-2.
[20]万军,何基德.甘草酸二铵注射液联合肝炎灵注射液治疗慢性乙型肝炎的疗效.浙江中医药大学学报,2007,31(3)：319-320.
[21]杨珊明,周建芳.贺普丁耐药的慢性乙型肝炎联合肝炎灵或迈普新疗效观察.实用药物与临床,2007,10(3)：147-149.
[22]车军勇.邵铭主任医师治疗慢性乙型肝炎经验.云南中医中药杂志,2007,28(1)：5-6.
[23]陈新瑜.罗本清主任医师治疗乙型肝炎经验.中国中医急症.2005,14(10)：983-984.
[24]李卫强,朱西杰.常占杰治疗慢性乙型肝炎经验.辽宁中医杂志,2007,34(7)：879-880.
[25]刘奇志.金实教授从“毒”论治病毒性肝炎学术思想举隅.河北中医,2006,28(3)：166-167.
[26]刘绪银,石凯歌.石海澄老中医治疗乙型肝炎的经验.湖南中医药导报,2000,6(11)：18-19.
[27]周卓宁.荣远明教授治疗慢性病毒性乙型肝炎的经验.广西中医药,2005,28(3)：41-42
[28]何方敏.孙同郊治疗慢性肝炎的经验介绍.云南中医中药杂志,2005,26(5)：6-7.
[29]张玮.王育群以活血化瘀法治疗病毒性肝炎经验举隅.安徽中医临床杂志,2001,13(6)：456-457.
[30]王文林.尤松鑫辨治慢性乙型肝炎的经验.中国校医,2005,19(1)：93.
[31]杨毅.刘国强教授中西医结合研究慢性乙型肝炎的思路.陕西中医,2007,28(9)：1212-1213.
[32]方亚祥,龙爱华.卫气营血辨证在病毒性肝炎治疗中的运用.江苏中医药,2003,24(11)：55-56.
[33]刑练军,季光,王育群,等.乙肝辨证分型与病毒复制关系的初步研究.辽宁中医杂志,2001,28(12)：710-711.
[34]叶永安,江锋,赵志敏,等.慢性乙型肝炎中医证型分布规律研究.中医杂志,2007,48(3)：256-258.
[35]中国中医药学会内科肝病专业委员会.病毒性肝炎中医辨证标准(试行)[J].中医杂志,1992,33(5)：391.
[36]刘绍能,陶夏平,王融冰,等.慢性乙型肝炎中医证候演变规律研究.中国中医药科技,2008,15(3)：161-164.
[37]王宝珍,刘成,薛惠明.慢性乙型肝炎肝纤维化中医证型与肝组织病理分级、分期关系的探讨.上海中医药杂志,2001,(12)：10-12.
[38]吴福宁,张猛.慢性乙型病毒性肝炎中医证型与肝功能指标的相关性研究.安徽中医学院学报,2003,22(6)：24-25.
[39]许晓东,张剑.慢性乙肝细胞免疫状态与辨证分型探讨.北京中医,2001,20(2)：56-57。
[40]吴全学.周信有教授辨治病毒性乙型肝炎经验拾零.甘肃中医,2005,18(8)：13-14.
[41]江锋,王宗殿.中医证候本质研究的回顾与思考.中医药学刊,2005,23(1)：131-133.
[42]郝建梅,凌蔓芝,杨彩虹.杨震主任医师应用相火论辨治乙肝的学术思想.陕西中医,2005,26(9)：27.
[43]管益红,苏和平.肝藏血在治疗乙肝中的临床意义.陕西中医,2004,25(1)：60
[44]陈文柯.慢性乙肝的中医辨证论治.实用中医内科杂志,2003,6：469-470.
[45]彭勇,徐学义教授辨治肝病经验浅析.贵阳中医学院学报,2006,28(1)：13-14.
[46]冯崇廉.彭胜权教授治疗慢性病毒性肝炎经验.临床医药实践杂志,2007,16(6)：539-540.
[47]张毅,李金田.周信有教授辨治乙型肝炎的临证思路与经验,云南中医中药杂志,2006,27(6)：12-13.
[48]谢绍武.高波治疗慢性乙型肝炎经验.安徽中医临床杂志,2002,14(1)：38.
[49]赵钢,陈建杰.王灵台教授论补肾法为主治疗慢性乙型肝炎的机制.中国中西医结合杂志,2005,25(1)：78-80.
[50]陆宁,赵湖珊.苦参素联合治疗慢性乙肝疗效观察[J].辽宁中医杂 志,2003,30(1)：38-39.
[51]丁国锋,程振兰,刘铭.中西医结合治疗慢性乙型肝炎42例疗效观察[J].新中医,2003,35(4)：38-39.
[52]黎民希,李强,何伟彬,等.拉米夫定联合中药煎剂治疗慢性乙型肝炎临床观察,实用肝脏病杂志,2006,9(5)：302-304.
[53]崔德广,龚伟峰.按阴阳辨证分类组方联合拉米夫定治慢性乙型肝炎临床研究.亚太传统医药,2007,3(7)：62-63.
[54]廖永州,古学文.双虎清肝颗粒联合拉米夫定治疗儿童慢性乙型肝炎68例.中西医结合肝病杂志,2005,15(5)：296-297.
[55]王志宏,岳蓓,朴兰意,等.针刺联合α干扰素治疗慢性乙型肝炎临床研究[J].临床肝胆杂志,2002,18(3)：187.
[56]韩扬,陈力,江漪,等.肝炎灵穴位治疗慢性乙型肝炎的临床研究[J].中西医结合肝病杂志,2002,12(5)：274-275.
[57]胡卫东,杨浩明,胡晓波,等。中药配合灸法治疗慢性活动性乙型病毒性肝炎,湖北中医杂志,2005,27(7)：22.
[58]Scaglioni PP, Melegari M, Wands JR. Biologic properities of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology,1997,233:374-381.
[59]Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis,2003,36:687-696.
[60]Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat,2002,9:243-257.
[61]Huy TTT, Ngoc TT,Abe K.New complex recombinant genotype of hepatitis B virus identified in Vietnam[J].J Virol,2008,82(11):5657-5663.
[62]Olinger CM, Jutavi jittum P, HubschenJM, et al. Possible new hepatitis B virus genotype,southeast Asia[J]. Emerg Infect Dis,2008,14(11)1777-1780.
[63]Biswas A, Chandra PK, Datta S, etal. Frequency and distribution of hepatitis B virus genotypes among eastern Indian voluntary blood donors:Association with precore and basal core promoter mutations[J]. Hepatol Res,2009,39(1):53-59.
[64]Qin Y, Zhang J, Mao R, etal. Prevalence of basal core promoter and precore mutations in Chinese chronic hepatitis B patients and corralation with serum HbeAgtiters[J]. J Med Virol,2009,81(5):807-814.
[65]SungJJ, Tsui SK, Tse CH, et al. Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus[J]. Jvirol,2008,82(7):3604-3611.
[66]Zhang KY, Imazeki F,Fukai K, et al. Analysis of complete hepatitis B virus genome in patients with genotype C chronic hepatitis and hepatocellular carcinoma[J],Cancer Sci,2007,98(12):1921-1929.
[67]Chan HL, Hui AY, Wong ML,et al. Genotype C hepatitis B virus infection is associated with an increased risk hepatocellular carcinoma[J]. Gut,2004,53(10):1494-1498.
[68]HubschenJM, Mugabo J, Peltier CA, et al. Exceptional genetic variability of hepatitis B virus indicates that Rwanda is east of an emerging African genotype E/Al divide[J].J Med Virol,2009,81 (3):435-440.
[69]Zhang HW,Yin JH,Li YT,etal.Risk factor for acute hepatitis B and its Progression to chronic hepatitis in Shanghai,China[J]. Gut,2008, 57(12):1713-1720.
[70]Hou J, Schilling R, Janssen HL,et al.Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance [J]. J Med Virol,2007,79(8):1055-1063.
[71]Liu CJ,Kao JH. Genetic variability of hepatitis B virus and response to antiviral therapy[J]. Antivir Ther,2008,13(5):613-624.
[72]Jardi R,Rodriguez-Frias F,Schaper M, et al.Analysis of hepatitis B genotype changes in chronic hepatitis B infection:Influence of antiviral therapy[J]. J Hepatol,2008,49(5):695-701.
[73]Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev, 2000,64(1):51-68.
[74]Kim WR. Epidemiology of hepatitis B in United State[J]. Hepatology,2009, 49(suppl15):S28-S34.
[75]戴志澄,祁国明.中国病毒性肝炎血清流行病学调查.上卷.北京：科学技术文献出版社,1997：21-35
[76]梁晓峰,陈园生,王晓军,等.中国3岁以上人群乙型肝炎血清流行病学研究.中华流行病学杂志,2005：26：655-658
[77]庄辉.乙型肝炎流行病学研究进展[J].国外医学·流行病学传染病学分册,2004,31(3)：133-135.
[78]WorldHealth Organization. Fact Hepatitis B Vaccine [EB/OL]. http://www.who . in/immunization delivery/new vaccine/4. Core information Hepatitis% 20B.pdf
[79]夏国良,刘崇柏,颜天强,等.乙型肝炎疫苗试点区免疫儿童乙型肝炎病毒标志物的分布[J].中华实验和临床病毒杂志,1995,9(增刊)：17-23.
[80]Li H, Li RC, Liao SS, et al. Long-term persistence of immunological memory for HBsAg after initial hepatitis B vaccine immunoprophylaxis[J]. ChinMed Sci J,1999,14 (suppl):17-20.
[81]李荣成,杨进业,王树声,等.乙型肝炎疫苗免疫后10年人群乙型肝炎标志物的人调查[J].中华实验和临床病毒杂志,1995,9(增刊)：32-36.
[82]夏国良,贾志远,颜天强,等.新生儿单纯乙型肝炎血源疫苗的免疫持久性和远期保护效果[J].中华实验和临床病毒杂志,2002,16(2)：146-149.
[83]卫生部公布全国人群乙肝血清流行病学调查结果,我国乙肝免疫预防工作取得显著成绩[EB/OL]. http://61.49.18.102/newshtml/21624. htm.
[84]戴志澄,齐国明.中国病毒性肝炎：血清流行病学调查[M].北京：科学技术出版社,1997：39-58.
[85]龚晓红,刘立荣,贾蕾,等.北京市新生儿接种乙型肝炎疫苗的流行病学效果评价[J].中华肝脏病杂志,2003,11(4)：201-202.
[86]吴疆,张伟,韩莉莉,等.北京市人群乙型肝炎血清流行病学调查[J].中华流行病学杂志,2007,28(6)：555-557.
[87]Lin HH,Wang LY, Hu CT,et al. Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects:sixteen years after newborn vaccination program in Taiwan[J]. Jmed Virol,2003,69(4):471-474.
[88]Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children Taiwan Childhood Hepatoma Study Group[J].N Eng J Med,1997,336(26):1855-1859.
[89]李荣成,杨进业,龚建,等.乙型肝炎疫苗预防原发性肝细胞癌的疗效评价[J].中华流行病杂志,2004,25(5)：385-387.
[90]Giusti G, Galanti B, Gaeta GB, et al. Clinical presentation and natural history of chronic persistent hepatitis.A multicenter retrospective study on 1197 cases[J]. Ital Gastroenterol,1991,23(3):111-118.
[91]Gaeta GB, Stornaiuolo G, Precone DF, et al. Epidemiological and burden of chronic hepatitis B virus/hepatitis C virus infection, A multicenter Italian study[J]. J Hepatol,2003,39(6):1036-1041.
[92]World Health Organization. Hepatitis B fact sheet,2002[EB/OL]. http://www.who. int/vaccine/hepatitisb. shtml. Accessed.
[93]骆抗先.乙型肝炎基础与临床.北京：人民卫生出版社,2006：247-248,252.
[94]Wang JS, Zhu QR, Wang XH. Breastfeeding does not pose any additional risk of immunoprophylaxis failure on infants of HBV carrier mothers. Int J Cli Pract, 2003; 57(2):100)
[95]Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HbeAg serocoversion inpatients with chronic hepatitis B. Hepatology,2002,35:1522-1527.
[96]Di Marco V, Lo Lacono O, Camma C, et al. The long-term course of chronic hepatitisB. Hepatology,1999,30:257-264.
[97]De Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. J Hepatol,2003,39 (Supply):S3-S25.
[98]Yang HI,Lu SN,Liaw YF,etal.Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med,2002,347:168-174.
[99]Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat,2004,11:97-107.
[100]Tai DI, Chen CH, Chang TT, et al. Eight-year nationwide survival analysis in relatives of patients with hepatocellular carcinoma:role of viral infection. J Gastroenterol Hepatol,2002, 17:682-689.
[101]Tsai SL.Sheen IS, Chien RN, et al.Activation of Thl immunity of a common immune mechanism for the successful treatment of hpatios B and C:tetramer assay and therapeutidc implications[j].Biomed Sci,2003,10:120-135
[102]Michelin MA, Crott LS, Assis-Pandochi Al, etal. Influence of the electric cha-rge of the antigen and the immune complex (IC) lattice on the IC activation of human complement..Int J Exp Pathol,2002,83(2):105-110
[103]Trepo C, Guillevin L. Polyarteritis nodosa and extrahepatic manifestations of HBV infection:the case against autoimmune intervention in pathogenesis. J Autoimmun.2001 May;16(3):269-74.
[104]《慢性乙型肝炎防治指南》中华医学会肝病学分会、中华医学会感染病学分会,2005.12.
[105]Lampertico P, DelNinno E, Manzin A, etal. A randomized,controlled trial of a 24-month course of interferon alpha 2b in patients with chronic Hepatitis B who had hepatitis B virus DNA without hepatitis e antigen in serum. Hepatology,1997,26(6):1621-1625.
[106]Fattovich G,Farci P,Rugge M, etal. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology,1992,15(4):584-589.
[107]Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatmen of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology, 2001,121(1):101-109.
[108]Amarapurkar DN,Patel ND. Combination of peginterferon Alpha-2b(12kD) and lamivudine in difficult-to-treat chronic hepatitis B an Indian experience[J]. Ann Hepatol,2005,4(1):56-59.
[109]Cooksley WG, Piratvisuth T, LeeSD, etal. Peginterferon alpha-2a(40kDa):an advance in the treatment of hepatitis B e antigen-positive Chronic hepatitis B. J Viral Hepat,2003,10(4):298-305.
[110]Lok AS, Lai CL, Leung N,et al.Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology,2003,125(6):1714-1722.
[111]Dienstag JL, Goldin RD, Heathcote EJ, etal. Histological outcome duringlong term lamivudine therapy. Gastroenterology,2003,124(1):105-117.
[112]Liaw YF, Sung JJ, Chow WC, etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med,2004,351(15):1521-1531.
[113]Hann HW, Fontana RJ, Wright T, et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl,2003,9(1):49-56.
[114]Figlerowicz M, Kowala-Piaskowska A, Filipowicz M, et al. Efficacy of lamivudine inthe treatment of children with chronic hepatitis B. Hepatol Res,2005, 31 (4):217-222.
[115]姚光弼,王宝恩,崔振宇,等.拉米夫定治疗慢性乙型肝炎三年疗效观察.中华内科杂志,2003,42(6)：382-387.
[116]姚光弼,崔振宇,姚集鲁,等.国产拉米夫定治疗2200例慢性乙型肝炎的Ⅳ期临床试验.中华肝脏病杂志,2003,11(2)：103-108.
[117]Marcellin P, Chang TT, Lim SG, et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med,2003,348(9): 808-816.
[118]Minde Z, Yimin M, Guangbi Y, et al. A double blind randomized trial of adefovir dipivoxil in Chinese subjects with HbeAg positive chronic hepatitis B[J]. Hepatology,2006,43(1):108-116.
[119]陆宁,徐园.阿德福韦酯联合苦参素治疗YMDD变异慢性乙型肝炎患者的疗效.中国医院药学杂志,2008,28(17)：1484-1486.
[120]Peters MG, Hann HwH, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine resistant chronic hepatitis B. Gastroenterology,2004,126(1):91-101.
[121]Perrillo R,Hann HW, Mutimer D, et al.Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology,2004,126(1):81-90.
[122]吴锦瑜,黎明,郎梅春.阿德福韦酯治疗YMDD变异的乙型肝炎肝硬化患者近期疗效观察.肝脏,2006,11(3)：215-216.
[123]Qi X, Snow A, Thibault V, et al, Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy. J Hepatol,2004,40(suppl1):20-21.
[124]Izzedine H, Hulot JS, Launay Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B:two double-blind, randomized, placebo-controlled studies. Kidney Int,2004,66(3):1153-1158.
[125]Colonno, RJ, Genovesi EV, Medina I, et al. Long-term entecavir treatment result in sustained antiviral efficacy and prolonged life span in the wood chuck model of chronic hepatitis in fection[J].J Infect Dis,2001,184(10):1236-1245.
[126]Marion PL, Salazar FH, Winters MA, et al. Potent efficacy of entecavir(Bms-200475) in a duck model of hepatitis B virus replication[J]. Antimicrob Agents Chemother,2002,46(1):82-88.
[127]Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology,2002,123(6):1831-1838.
[128]Chang T. Entecavir is superior to Lamivudine for the treatment of HbeAg(+) chronic hepatitis B:results of phase Ⅲ study ETV-022 in nucleoside-naive patients [J].Hepatology,2004,40(4Suppl1):193A.
[129]姚光弼,任红,王宝恩,等.恩替卡韦治疗拉米夫定失效的慢性乙型肝炎患者多中心随机双盲对照临床研究.肝脏,2005,10(1)：2-4.
[130]Schiff ER. Entecavir 1. Omg is consistentently superior to lamivudine at 48 weeks across multiple baseline HBV disease characteristics in lamivudine refractory patients[J]. Hepatology,2004,40(4suppll):131
[131]Colonno RJ, Rose R, Levine SM, et al. Emergence of entecavir resistant hepatitis B virus after one year of therapy in phase II&III studies is only observed in lamivudine refractory patients. Hepatology,2004,40(4suppll):661A.
[132]Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis R e antigen-positive chronic hepatitis B. Gastroenterology,2005,129 (2):528-536.
[133]Lai CL, Gane E, Hsu CW, et al. Two-Year Results from the GLOBE Trial in Patients with Hepatitis B:Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine. Hepatology,2006,41 (4 Suppl1):222A.
[l34]Bzowej N, Chan LYH, Lai CL, et al. A randomized trial of telbivudine(LdT) vs. adefovir for HBeAg-positive chronic hepatitis B:final week 52 results. Hepatology,2006,44(4Suppl 1):563A.
[135]LAU G, COOKSLEY H, RIBEIRO R M, et al. Double-blind study comparing adefovir dipivoxil (ADV)plus emtricitabine(Frc) combination therapy versus ADV alone in HBeAg+chronic hepatitis B:Efficacy and mechanisms of treatment response [J]. Hepatology,2004,40(4Suppl1):272A.
[136]DANDO T M,WAGSTAFF A J.Emtrieitabine/tenofovir disoproxil fumarate[J]. Drugs, 2004,64(18):2075-2082.
[137]STEVENS RC, BLUM MR, ROUSSEAU FS, etal. Intracel lular pharmacology of emtricitabine and tenofovir[J]. Clin Infect Dis,2004,15(6):877-878.
[138]Gish RG,Trinh H,Leung N, et al. Safety and antiviral ativity of emtricitabine(FTC) for the treatment of chronic hepatitis B infection:a two-year study [J]. J Hepatol,2005,43 (1):60-66.
[139]Marcellin P, Mommeja-Marin H, Sacks SL,et al. A phase Ⅱ dose escalatine trial of clevudine in patients with chronic hepatitis B[J]. Hepatology,2004,40(1):140-148.
[140]Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofowir in HIV-1 and hepatitis B virus co-infected individual[J]. AIDS,2003,17(1):F7-10.
[141]Van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine resistant hepatitis B virus(HBV)infection[J].Hepatology,2004,40(6):1421-5.
142]刘秦.抗乙肝药物ACH-126443[J].药学进展,2004,28(3)：140.
[143]吴荻,牛俊奇,吴新宇,等.一种新型MCC-478衍生物抗乙型肝炎病毒活性及体外毒性实验.吉林大学学报(医学版),2007,33(3)：422-426.
[144]Chao-Pin Li,Li-Fa Xu,Chao Zhang,etal.Extraction of protoporphyrin disodium and its inhibitory effects on HBV-DNA.World J Gastroenterol,2004,10(3):433-6.
[145]范巧云,刘群红,李朝品,等.原卟啉钠的制备及其体外抗乙型肝炎病毒作用的实验性研究.陕西医学杂志,2006,35(11)：1443-1445.
[146]雷延昌,马涛,郝友华,等.载脂蛋白质B mRNA编辑酶催化多肤3G抑制乙型肝炎病毒和鸭乙型肝炎病毒复制.中华肝脏病杂志,2006,14(10)：738-741.
[147]李声方,方兮,桂希恩,等.当归多糖对HBV转基因小鼠树突状细胞功能状态的影响.实用诊断与治疗杂志,2005,19(5)：313-314.
[148]Samuel CE.Antiviral actions of interferons[J].Clin Microbiol Rev,2001,14:778-809.
[149]Chee AV,Roizman B. Herpes simplex virus 1 gene products occlude the interferon signaling pathway at multiple sites[J].J Virol,2004,78(8):4185-4196.
[150]张权,魏来,王燕ISGF3:IFN-α抗乙型肝炎病毒信号转导机制的重要因子.中华实验和临床病毒学杂志,2005,19(2)：110-113.
[151]盛国光,黄腊平,晏雪生,等.海珠益肝胶囊胶囊对HepG2.2.15细胞Fas、Bax、bcl-2的影响.实用肝脏病杂志,2003,6(2)：70-72.
[152]李莉,唐冲华,余光开,等.抑毒调平液对Th 1/Th2细胞平衡的调节及其抗乙型肝炎病毒活性的研究.中华肝脏病杂志,2003,11(4)：247
[153]Li SF,Wang X,Gui XE,et al.Effects of angelica polysaccharide on the functional status of dendritic cells in HBC trans-genic mice[J].J Pract Diang Ther,2005,19(5):313-315.
[154]张红栓,杨运高,华何与,等.乙肝扶正排毒胶囊体外抗乙肝病毒及对NF-kb活化干预的实验研究.湖南中医杂志,2006,22(3)：84-86
[155]Levent G, Ali A, Ahmet A, Polat EC, Aytac C, Ayse E, Ahmet S. Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy. J Transl Med 2006,4:25.
[156]Dikici I, Mehmetoglu I, Dikici N,etal. Investigation of oxidative stress and some antioxidants in patients with acute and chronic viral hepatitis B and the effect of interferon-alpha treatment. Clin Biochem,2005,38(12):1141-1144.
[157]Piccoli C, Scrima R, Quarato G, etal.Hepatitis C virus protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-oxidative stress. Hepatology 2007,46(1):58-65
[158]McClain SL, Clippinger AJ, Lizzano R, etal. Hepatitis B virus replication is associated with an HBx-dependent mitochondrion-regulated increase in cytosolic calcium levels. J Virol 2007,81(21):12061-12065.
[159]Zhang W, Cox AG, Taylor EW. Hepatitis C virus encodes a selenium-dependent glutathione peroxidase gene. Implications for oxidative stress as a risk factor in progression to hepatocellular carcinoma. Med Klin (Munich),1999,94 (Suppl 3):2-6.
[160]Jiang B F, Xu X F, Li L,et al. Study on"911"Anti-HBVEffect in Hep G2.2.215 cells culture [J].Modern Prev Med,2003,30(4):517.
[161]扶云碧,张广森BCR/ABL癌基因启动JAK/STAT信号转导途径的机制后果及意义.外医学输血及血液学分册,2001,24(6)：473-475.
[162]毛国强,许红梅,朱朝敏.MxA蛋白研究进展[J].国外医学病毒学分册,2005,12：107-110.
[163]管世鹤,杨东亮,陆蒙吉.干扰素抗病毒蛋白MxA和2',5'-OAS在肝胚瘤细胞株中的差异表达.中国感染与化疗杂志,2006,6(3)：149-153
[164]Spudich A, Frigg R, Kilic E, et al. Aggravation of ischemic brain injury by prion protein deficiency:role of ERK-1/-2 andSTAT-1 [J]. Neurobiol Dis,2005,20(2):442-449.
[165]杨馨,李继书,杨慎峭,等.艾灸对实验性类风湿性关节炎家兔滑膜细胞JAK/STAT信号通路影响的研究.针刺研究,2007,32(2)：75-79.
[166]王松柏,孙家潭JAK/STAT通路对脓毒症大鼠肝组织IL-10表达的影响.张家口医学院学报,2003,20(4)：14-16.
[167]沈诚,范士志,陈建明,等JAK/STAT通路对缺血再灌注心肌NF-κB和Caspase-3表达的影响.中国误诊学杂志,2006,6(1)：6-8.
[168]周凤桐,陶国才,王松柏,等.感染性休克大鼠JAK/STAT对组织IFN-Y表达的影响.第三军医大学学报,2006,28(15)：1585-1587.
[169]张芸,赵中夫,韩德五,等.雷帕霉素抑制JAK/STAT通路对急性肝损伤大鼠肝组织HMGB1表达的影响.世界华人消化杂志,14(19)：1916-1920.
[170]郑敏,卢葵花,吴基良,等.大蒜多糖体外抗乙型肝炎病毒作用研究.中药药理与临床2005,21(3)：29-30.
[171]鲁小杰,黄正明,杨新波,等.金丝桃苷对鸭HBV感染的保肝作用.中药药理与临床2007,23(2)：10-12.
[172]徐庆,宋芸娟,李丽亚,等.荔枝核总黄酮的抗鸭乙型肝炎病毒作用.世界华人消化杂志2005,13(17)：2082-2085.
[173]刘中景,熊曼琪,张洪来.小柴胡汤抗鸭乙肝病毒的实验研究.中国中西医结合杂志,2000,20(11)：853-855.
[174]Sells M A. Production of hepatitis B virus particles in HepG2 cells transfected witll cloned hepatitis B virus DNA[J]. Proc Nail Acad Sci USA,1987,84(4):1005-1009.
[175]Sells MA,Zelent AZ,Shvartsman M,etal.Replicative intermediates of hepatitis Bvirus in HepG2 cells that produce infectious virions.J Virol,1988,62(8):2836-2844.
[176]徐陈槐,刘克洲,何南祥,等.鸭乙型肝炎动物模型的建立和DHBV在肝脏的定位研究[J].中国人兽共患病杂志,1994,10(6)：2-5.
[177]Kundgen LR,Thoma C,Kock J,etal.Inhibition of duck hepatitis Bvirus replication by intrahepatic expression of an antiviral resistance gene[J].JMolMed,2002,80(3):187-195.
[178]朱清静,聂广,李翰旻,等.鸭乙型肝炎肝纤维化模型的研究[J].临床与实验病理学杂志,2000,16(6)：501-502.
[179]Breiner KM,Urban S,Glass B,etal.Envelope protein-mediated down-regulation of hepatitis B virus receptor in infected hepatocytes.JVirol,2001,75(1):143-150.
[180]Urban S.Binding of duck carboxypeptidase D to duck hepatitis B virus.Methods MolMed,2004,95:199-212.
[181]陈压西,郭树华,齐珍元,等.叶下珠有效部位抗鸭乙型肝炎病毒及体外抗HBV活性的研究.中药药理与临床,1999,15(6)：16-18
[182]彭立生,贺劲松,童光东,等.叶下珠提取物抗乙肝病毒及乙肝病毒X基因的研究.中西医结合肝病杂志,2006,16(6)：340-340.
[183]李向荣,陈琳,郭靖,等.叶下珠对HBVM的影响100例报告.实用新医学,2001,3(1)：39.
[184]周军,李茂,樊亦军.叶下珠醇提物对实验性肝损伤的保护作用.广西中医学院学报,2004,7(1)：5-7.
[185]冯天保,田广俊,李华,等.福建叶下珠抗小鼠免疫性肝损伤的实验研究.中药新药与临床药理,2005,16(3)：343-345.
[186]蔡树华,蒋如华.叶下珠对小鼠酒精性肝损伤的保护作用.实用肝脏病杂志,2007,10(1)：19-21.
[187]侯周华,谭德明.苦参碱治疗慢性乙型肝炎的临床研究[J].实用预防医学,2005,12(4)：824-826.
[188]王啸,董香玉,朱传安.苦参素对慢性乙型肝炎外周血T淋巴细胞亚群的影响[J].临床荟萃,2001,16(18)：841.
[189]赵洪莹.苦参素注射液治疗慢性乙型肝炎后肝纤维化的疗效[J].中华腹部疾病杂志,2005,5(6)：449-450.
[190]孙其山,丁蔚芋,李亚峰.肝苏颗粒治疗病毒性肝炎386例[J].中西医结合肝病杂志,2001,11(6)：355-356.
[1]李卫强,朱西杰.常占杰治疗慢性乙型肝炎经验.辽宁中医杂志,2007,34(7)：879-880.
[2]张红栓,杨运高,华何与,等.乙肝扶正排毒胶囊体外抗HBV及对NF-kB活化干预的实验研究.湖南中医杂志,2006,22(3)：84-86.
[3]刘丽丽,李常青,朱宇同,等.清肝排毒饮抗鸭乙型肝炎病毒的实验研究.中国热带医学,2007,7(2)：193-195.
[4]陈诗慧,莫运涛.疏肝健脾祛湿中药体内抗鸭乙型肝炎病毒的实验研究.中国医药导报,2008,5(13)：25-26.
[5]邱杰文,黄彩华,程红球,等.黄萱益肝散抗鸭乙型肝炎病毒及保护肝细胞的实验研究.现代中西医结合杂志,2008,17(14)：2128-2129.
[6]刘汉平,何金洋,梁波.扶正利湿活血复方对鸭胚肝细胞中鸭乙型肝炎病毒的抑制作用.时珍国医国药,2009,20(7)：1670-1672..
[7]李顺天,梁树人,李秀梅,等.戴茵兰益肝颗粒剂体外抑制乙型肝炎病毒复制的实验研究.天津中医药,2007,24(3)：236-237.
[8]党双锁,陈云茹,程延安,等.黄芪蛰虫合剂体外抗乙型肝炎病毒的作用观察.第四军医大学学报,2006,27(20)：1840-1842。
[9]林兴,黄权芳,张士军,等.六月青含药血清对HepG2.2.15细胞系HBsAg与HBeAg表达的影响.时珍国医国药,2009,2(7)：1603-1604.
[10]张士军,林兴,林军,等.复方六月雪含药血清对2.2.15细胞和的抑制作用.中成药,2007,29(6)：805-809.
[11]谭行华,王建,吴茂盛,等.愈肝胶囊对2.2.15细胞分泌HBsAg!HBeAg的抑制作用.中西医结合肝病杂志,2004,14(3)：158-160.
[12]谭行华,张爱民,余卫华,等.愈肝胶囊的抗鸭HBV作用研究.中药材,2005,28(8)：679-681.
[13]刘春荣,许小林,薛强,等.复方鬼辣椒根液对鸭乙型肝炎治疗作用的研究.右江医学,2007,35(3)：292-293.
[14]徐颖,黄正明,徐必学,等.苯丙氨酸二肽类化合物073对2.2.15细胞分泌HBsAg和HBeAg的影响.解放军药学学报,2009,25(2)：120-124.
[15]唐庆年,冯梅,龚受基,等.雪灵芝提取物对HepG2.2.15细胞株HBsAg与HBeAg表达的影响.中药材,2008,31(8)：1212-1215.
[16]Jiyang Li,HaiHuang,MeiqingFeng,etal.In vitro and in vivo anti-hepatitis B virus activities of a plant extract from Geranium carolinianum L. Antiviral Research,2008,79:114-12.
[17]Y.-L.Zhao,G.-M.Cai,X.Hong,etal.Anti-hepatitis B virus activities of triterpenoid saponin compoundfrom Potentilla anserine L. Phytomedicine,2008,15:253-258.
[18]杨柯,郑作文,欧贤红.广西藤茶提取物TTF含药血清对乙型肝炎病毒HBsAg和HBeAg的抑制作用.医药导报,2008,27(4)：390-392.
[19]杨柯,郑作文.广西藤茶提取物TTF抗鸭乙型肝炎病毒的实验研究.时珍国医国药,2007,18(11)：2634-2635.
[20]万新祥,张鑫,刘强,等.皱瘤海鞘体外抗HBV作用的初步研究.第一军医大学分校学报,2002,25(2)：84-85.
[21]李春荣,林晓春,陈广辉,等.皱瘤海鞘正丁醇部位体外抗HBV的初步研究.时珍国医国药,2007,18(9)：2116.
[22]李宝剑,金丽琴,左江成.细脚拟青霉多糖抗乙型肝炎病毒的体外实验研.中药材,2007,30(2)：200-203.
[23]黄华,王歆君,杨巧丽,等.布亚胶囊抗HBV作用的试验研究.新疆中医药,2009,27(4)：3-5.
[24]湛孝东,王克霞,李朝品.蜗牛多糖体外抗乙型肝炎病毒作用研究.中国实验方剂学杂志.2008,14(3)：66-68.
[25]刘妮,肖会泉,沈海容,等.小叶榕水提物对]HBsAg和HBeAg体外抑制作用的实验研究.浙江中西医结合杂志,2009,19(8)：486-490.
[26]谢琼,谭德明,彭忠田,等.脱氧野尻霉素抑制乙型肝炎病毒复制的体外实验研究.中国感染控制杂志,2009,8(1)：3-6.
[27]李永伟,郭云蔚,李刚,等.甘草甜素对HepG2.2.15细胞株HBV感染的影响.中国中医药信息杂志,2009,16(9)：31-33.
[28]饶敏,张淑玲,董继华,等.高三尖杉酯碱等四种药物的体外抑制HBV的实验研究.中国病毒学,2006,21(3)：284-287.
[29]吴晓蔓,袁文声.黄芪抗乙型肝炎病毒的体外实验研究.广东医学,2008,29(1)：37-38.
[30]陆伦根,曾民德,茅益民,等.氧化苦参碱治疗慢性乙型肝炎的随机双盲对照多中心研究.中华肝脏病杂志,2004,12(10)：597-600.
[31]平键,成扬,许怀栋,等.氧化苦参碱黄芩苷组合物抗乙型肝炎病毒和抗肝纤维化的体外实验.实用脏病杂志,2007,10(3)：148-151.
[32]吴荻,牛俊奇,吴新宇,等.一种新型MCC-478衍生物抗乙型肝炎病毒活性及体外毒性实验.吉林大学学报(医学版),2007,33(3)：422-426.
[33]蔡钦生,冯美卿,黄海,等.阿昔洛韦棕榈酰酯的高效合成!结构表征及其体外抗HBV的 作用.复旦学报(医学版),2007,34(4)：468-472.
[34]Chao-Pin Li,Li-Fa Xu,Chao Zhang,etal.Extraction of protoporphyrin disodium and its inhibitory effects on HBV-DNA.World J Gastroenterol,2004,10(3):433.
[35]范巧云,刘群红,李朝品,等.原卟啉钠的制备及其体外抗乙型肝炎病毒作用的实验性研究.陕西医学杂志,2006,35(11)：1443-1445.
[36]孟斌,温博贵,韩金祥.丁型肝炎病毒核酶的结构特点与催化作用机制.中国生物工程杂志,2003,23(8)：52-56.
[37]戚鹏,韩金祥,鲁艳芹,等.逆转录病毒靶向介导HDV核酶体外抑制HBV表达.中国生物制品学杂志,2007,20(4)：233-236.
[38]Oka Y,Akbar SM,Horiike N,etal.Mechanism and therapeutic potential of DNA-based immunization against the envelope proteins of hepatitis B virus in normal and transgenic mice[J].Immunology,2001,103(1):90-97.
[39]杨富强,陈光明,何晓嫱,等HBVDNA疫苗诱导健康及HBV转基因小鼠细胞免疫应答.解放军医学杂志,2003,28(6)：501-503.
[40]Harris RS, Bishop KN, Sheehy AM, et al. DNA deamination mediates innate immunity to retroviral infection. Cell,2003,113:803-809.
[41]雷延昌,马涛,郝友华,等.载脂蛋白质B mRNA编辑酶催化多肤3G抑制乙型肝炎病毒和鸭乙型肝炎病毒复制.中华肝脏病杂志,2006,14(10)：738-741.
[2]石光,谢永富,刘秀颖,等.乙型肝炎经济负担的测算.中国初级卫生保健,2004,18(8)：18-19.
[3]Lotrich FE, Rabinovitz M, Gironda P, etal. Depression following pegylated interferon alpha:characteristics and vulnerability.J Psychosom Res,2007,63 (2):131-5.
[4]赵鸿,斯崇文,魏来,等.聚乙二醇化干扰素α-2b与干扰素α-2b治疗e抗原阳性慢性乙型肝炎的疗效和安全性的随机对照多中心研究.中华肝脏病杂志,2006,14(5)：323-326.
[5]Liaw YF, Leung N, Guan R.Asian-Pacific consensus statement on the management of chronic hepatitis B:anupdate [J].J Gastroenterol Hepatol,2003,18(3):239-245.
[6]张友祥,王灵台,陈建杰.中药补肾冲剂联合拉米夫定治疗慢性乙型肝炎88例[J].中西医结合肝病杂志,2003,13(2)：112-113.
[7]邱杰文,黄彩华,程红球,等.黄萱益肝散抗鸭乙型肝炎病毒及保护肝细胞的实验研究.现代中西医结合杂志,2008,17(14)：2128-2129.
[8]刘汉平,何金洋,梁波.扶正利湿活血复方对鸭胚肝细胞中鸭乙型肝炎病毒的抑制作用.时珍国医国药,2009,20(7)：1670-1672..
[9]刘丽丽,李常青,朱宇同,等.清肝排毒饮抗鸭乙型肝炎病毒的实验研究.中国热带医学,2007,7(2)：193-195.
[10]陈诗慧,莫运涛.疏肝健脾祛湿中药体内抗鸭乙型肝炎病毒的实验研究.中国医药导报,2008,5(13)：25-26.
[11]张永兴.神奇的抗病毒中草药[M].北京,中国中医药出版社,2004年第1版
[12]黄祝青,龚守军,孙永年,等.苦参素治疗慢性乙型肝炎疗效分析[J].肝脏,2002,7(1)：67-68.
[13]李宝剑,金丽琴,左江成.细脚拟青霉多糖抗乙型肝炎病毒的体外实验研.中药材,2007,30(2)：200-203.
[14]黄华,王歆君,杨巧丽,等.布亚胶囊抗HBV作用的实验研究.新疆中医药,2009,27(4)：3-5.
[15]湛孝东,王克霞,李朝品.蜗牛多糖体外抗乙型肝炎病毒作用研究.中国实验方剂学杂志.2008,14(3)：66-68.
[16]谢琼,谭德明,彭忠田,等.脱氧野尻霉素抑制乙型肝炎病毒复制的体外实验研究.中国感染控制杂志,2009,8(1)：3-6.
[17]李烨,王新华,卢梅生,等.混血穴位注射疗法治疗慢性乙型肝炎54例[J].中西医结合肝病杂志,2003,13(4)：200-201.
[18]徐金波,邹永芬.中药联合干扰素及胸腺因子D治疗慢性乙型肝炎53例观察[J].实用中药,2003,19(1)：26-27.
[19]蔡红兵,徐舒,李洪,等.逍遥丸联合阿德福韦治疗肝郁脾虚型慢性乙型肝炎疗效观察.湖南中医杂志,2007,23(5)：1-2.
[20]万军,何基德.甘草酸二铵注射液联合肝炎灵注射液治疗慢性乙型肝炎的疗效.浙江中医药大学学报,2007,31(3)：319-320.
[21]杨珊明,周建芳.贺普丁耐药的慢性乙型肝炎联合肝炎灵或迈普新疗效观察.实用药物与临床,2007,10(3)：147-149.
[22]车军勇.邵铭主任医师治疗慢性乙型肝炎经验.云南中医中药杂志,2007,28(1)：5-6.
[23]陈新瑜.罗本清主任医师治疗乙型肝炎经验.中国中医急症.2005,14(10)：983-984.
[24]李卫强,朱西杰.常占杰治疗慢性乙型肝炎经验.辽宁中医杂志,2007,34(7)：879-880.
[25]刘奇志.金实教授从“毒”论治病毒性肝炎学术思想举隅.河北中医,2006,28(3)：166-167.
[26]刘绪银,石凯歌.石海澄老中医治疗乙型肝炎的经验.湖南中医药导报,2000,6(11)：18-19.
[27]周卓宁.荣远明教授治疗慢性病毒性乙型肝炎的经验.广西中医药,2005,28(3)：41-42
[28]何方敏.孙同郊治疗慢性肝炎的经验介绍.云南中医中药杂志,2005,26(5)：6-7.
[29]张玮.王育群以活血化瘀法治疗病毒性肝炎经验举隅.安徽中医临床杂志,2001,13(6)：456-457.
[30]王文林.尤松鑫辨治慢性乙型肝炎的经验.中国校医,2005,19(1)：93.
[31]杨毅.刘国强教授中西医结合研究慢性乙型肝炎的思路.陕西中医,2007,28(9)：1212-1213.
[32]方亚祥,龙爱华.卫气营血辨证在病毒性肝炎治疗中的运用.江苏中医药,2003,24(11)：55-56.
[33]刑练军,季光,王育群,等.乙肝辨证分型与病毒复制关系的初步研究.辽宁中医杂志,2001,28(12)：710-711.
[34]叶永安,江锋,赵志敏,等.慢性乙型肝炎中医证型分布规律研究.中医杂志,2007,48(3)：256-258.
[35]中国中医药学会内科肝病专业委员会.病毒性肝炎中医辨证标准(试行)[J].中医杂志,1992,33(5)：391.
[36]刘绍能,陶夏平,王融冰,等.慢性乙型肝炎中医证候演变规律研究.中国中医药科技,2008,15(3)：161-164.
[37]王宝珍,刘成,薛惠明.慢性乙型肝炎肝纤维化中医证型与肝组织病理分级、分期关系的探讨.上海中医药杂志,2001,(12)：10-12.
[38]吴福宁,张猛.慢性乙型病毒性肝炎中医证型与肝功能指标的相关性研究.安徽中医学院学报,2003,22(6)：24-25.
[39]许晓东,张剑.慢性乙肝细胞免疫状态与辨证分型探讨.北京中医,2001,20(2)：56-57。
[40]吴全学.周信有教授辨治病毒性乙型肝炎经验拾零.甘肃中医,2005,18(8)：13-14.
[41]江锋,王宗殿.中医证候本质研究的回顾与思考.中医药学刊,2005,23(1)：131-133.
[42]郝建梅,凌蔓芝,杨彩虹.杨震主任医师应用相火论辨治乙肝的学术思想.陕西中医,2005,26(9)：27.
[43]管益红,苏和平.肝藏血在治疗乙肝中的临床意义.陕西中医,2004,25(1)：60
[44]陈文柯.慢性乙肝的中医辨证论治.实用中医内科杂志,2003,6：469-470.
[45]彭勇,徐学义教授辨治肝病经验浅析.贵阳中医学院学报,2006,28(1)：13-14.
[46]冯崇廉.彭胜权教授治疗慢性病毒性肝炎经验.临床医药实践杂志,2007,16(6)：539-540.
[47]张毅,李金田.周信有教授辨治乙型肝炎的临证思路与经验,云南中医中药杂志,2006,27(6)：12-13.
[48]谢绍武.高波治疗慢性乙型肝炎经验.安徽中医临床杂志,2002,14(1)：38.
[49]赵钢,陈建杰.王灵台教授论补肾法为主治疗慢性乙型肝炎的机制.中国中西医结合杂志,2005,25(1)：78-80.
[50]陆宁,赵湖珊.苦参素联合治疗慢性乙肝疗效观察[J].辽宁中医杂 志,2003,30(1)：38-39.
[51]丁国锋,程振兰,刘铭.中西医结合治疗慢性乙型肝炎42例疗效观察[J].新中医,2003,35(4)：38-39.
[52]黎民希,李强,何伟彬,等.拉米夫定联合中药煎剂治疗慢性乙型肝炎临床观察,实用肝脏病杂志,2006,9(5)：302-304.
[53]崔德广,龚伟峰.按阴阳辨证分类组方联合拉米夫定治慢性乙型肝炎临床研究.亚太传统医药,2007,3(7)：62-63.
[54]廖永州,古学文.双虎清肝颗粒联合拉米夫定治疗儿童慢性乙型肝炎68例.中西医结合肝病杂志,2005,15(5)：296-297.
[55]王志宏,岳蓓,朴兰意,等.针刺联合α干扰素治疗慢性乙型肝炎临床研究[J].临床肝胆杂志,2002,18(3)：187.
[56]韩扬,陈力,江漪,等.肝炎灵穴位治疗慢性乙型肝炎的临床研究[J].中西医结合肝病杂志,2002,12(5)：274-275.
[57]胡卫东,杨浩明,胡晓波,等。中药配合灸法治疗慢性活动性乙型病毒性肝炎,湖北中医杂志,2005,27(7)：22.
[58]Scaglioni PP, Melegari M, Wands JR. Biologic properities of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology,1997,233:374-381.
[59]Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis,2003,36:687-696.
[60]Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat,2002,9:243-257.
[61]Huy TTT, Ngoc TT,Abe K.New complex recombinant genotype of hepatitis B virus identified in Vietnam[J].J Virol,2008,82(11):5657-5663.
[62]Olinger CM, Jutavi jittum P, HubschenJM, et al. Possible new hepatitis B virus genotype,southeast Asia[J]. Emerg Infect Dis,2008,14(11)1777-1780.
[63]Biswas A, Chandra PK, Datta S, etal. Frequency and distribution of hepatitis B virus genotypes among eastern Indian voluntary blood donors:Association with precore and basal core promoter mutations[J]. Hepatol Res,2009,39(1):53-59.
[64]Qin Y, Zhang J, Mao R, etal. Prevalence of basal core promoter and precore mutations in Chinese chronic hepatitis B patients and corralation with serum HbeAgtiters[J]. J Med Virol,2009,81(5):807-814.
[65]SungJJ, Tsui SK, Tse CH, et al. Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus[J]. Jvirol,2008,82(7):3604-3611.
[66]Zhang KY, Imazeki F,Fukai K, et al. Analysis of complete hepatitis B virus genome in patients with genotype C chronic hepatitis and hepatocellular carcinoma[J],Cancer Sci,2007,98(12):1921-1929.
[67]Chan HL, Hui AY, Wong ML,et al. Genotype C hepatitis B virus infection is associated with an increased risk hepatocellular carcinoma[J]. Gut,2004,53(10):1494-1498.
[68]HubschenJM, Mugabo J, Peltier CA, et al. Exceptional genetic variability of hepatitis B virus indicates that Rwanda is east of an emerging African genotype E/Al divide[J].J Med Virol,2009,81 (3):435-440.
[69]Zhang HW,Yin JH,Li YT,etal.Risk factor for acute hepatitis B and its Progression to chronic hepatitis in Shanghai,China[J]. Gut,2008, 57(12):1713-1720.
[70]Hou J, Schilling R, Janssen HL,et al.Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance [J]. J Med Virol,2007,79(8):1055-1063.
[71]Liu CJ,Kao JH. Genetic variability of hepatitis B virus and response to antiviral therapy[J]. Antivir Ther,2008,13(5):613-624.
[72]Jardi R,Rodriguez-Frias F,Schaper M, et al.Analysis of hepatitis B genotype changes in chronic hepatitis B infection:Influence of antiviral therapy[J]. J Hepatol,2008,49(5):695-701.
[73]Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev, 2000,64(1):51-68.
[74]Kim WR. Epidemiology of hepatitis B in United State[J]. Hepatology,2009, 49(suppl15):S28-S34.
[75]戴志澄,祁国明.中国病毒性肝炎血清流行病学调查.上卷.北京：科学技术文献出版社,1997：21-35
[76]梁晓峰,陈园生,王晓军,等.中国3岁以上人群乙型肝炎血清流行病学研究.中华流行病学杂志,2005：26：655-658
[77]庄辉.乙型肝炎流行病学研究进展[J].国外医学·流行病学传染病学分册,2004,31(3)：133-135.
[78]WorldHealth Organization. Fact Hepatitis B Vaccine [EB/OL]. http://www.who . in/immunization delivery/new vaccine/4. Core information Hepatitis% 20B.pdf
[79]夏国良,刘崇柏,颜天强,等.乙型肝炎疫苗试点区免疫儿童乙型肝炎病毒标志物的分布[J].中华实验和临床病毒杂志,1995,9(增刊)：17-23.
[80]Li H, Li RC, Liao SS, et al. Long-term persistence of immunological memory for HBsAg after initial hepatitis B vaccine immunoprophylaxis[J]. ChinMed Sci J,1999,14 (suppl):17-20.
[81]李荣成,杨进业,王树声,等.乙型肝炎疫苗免疫后10年人群乙型肝炎标志物的人调查[J].中华实验和临床病毒杂志,1995,9(增刊)：32-36.
[82]夏国良,贾志远,颜天强,等.新生儿单纯乙型肝炎血源疫苗的免疫持久性和远期保护效果[J].中华实验和临床病毒杂志,2002,16(2)：146-149.
[83]卫生部公布全国人群乙肝血清流行病学调查结果,我国乙肝免疫预防工作取得显著成绩[EB/OL]. http://61.49.18.102/newshtml/21624. htm.
[84]戴志澄,齐国明.中国病毒性肝炎：血清流行病学调查[M].北京：科学技术出版社,1997：39-58.
[85]龚晓红,刘立荣,贾蕾,等.北京市新生儿接种乙型肝炎疫苗的流行病学效果评价[J].中华肝脏病杂志,2003,11(4)：201-202.
[86]吴疆,张伟,韩莉莉,等.北京市人群乙型肝炎血清流行病学调查[J].中华流行病学杂志,2007,28(6)：555-557.
[87]Lin HH,Wang LY, Hu CT,et al. Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects:sixteen years after newborn vaccination program in Taiwan[J]. Jmed Virol,2003,69(4):471-474.
[88]Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children Taiwan Childhood Hepatoma Study Group[J].N Eng J Med,1997,336(26):1855-1859.
[89]李荣成,杨进业,龚建,等.乙型肝炎疫苗预防原发性肝细胞癌的疗效评价[J].中华流行病杂志,2004,25(5)：385-387.
[90]Giusti G, Galanti B, Gaeta GB, et al. Clinical presentation and natural history of chronic persistent hepatitis.A multicenter retrospective study on 1197 cases[J]. Ital Gastroenterol,1991,23(3):111-118.
[91]Gaeta GB, Stornaiuolo G, Precone DF, et al. Epidemiological and burden of chronic hepatitis B virus/hepatitis C virus infection, A multicenter Italian study[J]. J Hepatol,2003,39(6):1036-1041.
[92]World Health Organization. Hepatitis B fact sheet,2002[EB/OL]. http://www.who. int/vaccine/hepatitisb. shtml. Accessed.
[93]骆抗先.乙型肝炎基础与临床.北京：人民卫生出版社,2006：247-248,252.
[94]Wang JS, Zhu QR, Wang XH. Breastfeeding does not pose any additional risk of immunoprophylaxis failure on infants of HBV carrier mothers. Int J Cli Pract, 2003; 57(2):100)
[95]Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HbeAg serocoversion inpatients with chronic hepatitis B. Hepatology,2002,35:1522-1527.
[96]Di Marco V, Lo Lacono O, Camma C, et al. The long-term course of chronic hepatitisB. Hepatology,1999,30:257-264.
[97]De Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. J Hepatol,2003,39 (Supply):S3-S25.
[98]Yang HI,Lu SN,Liaw YF,etal.Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med,2002,347:168-174.
[99]Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat,2004,11:97-107.
[100]Tai DI, Chen CH, Chang TT, et al. Eight-year nationwide survival analysis in relatives of patients with hepatocellular carcinoma:role of viral infection. J Gastroenterol Hepatol,2002, 17:682-689.
[101]Tsai SL.Sheen IS, Chien RN, et al.Activation of Thl immunity of a common immune mechanism for the successful treatment of hpatios B and C:tetramer assay and therapeutidc implications[j].Biomed Sci,2003,10:120-135
[102]Michelin MA, Crott LS, Assis-Pandochi Al, etal. Influence of the electric cha-rge of the antigen and the immune complex (IC) lattice on the IC activation of human complement..Int J Exp Pathol,2002,83(2):105-110
[103]Trepo C, Guillevin L. Polyarteritis nodosa and extrahepatic manifestations of HBV infection:the case against autoimmune intervention in pathogenesis. J Autoimmun.2001 May;16(3):269-74.
[104]《慢性乙型肝炎防治指南》中华医学会肝病学分会、中华医学会感染病学分会,2005.12.
[105]Lampertico P, DelNinno E, Manzin A, etal. A randomized,controlled trial of a 24-month course of interferon alpha 2b in patients with chronic Hepatitis B who had hepatitis B virus DNA without hepatitis e antigen in serum. Hepatology,1997,26(6):1621-1625.
[106]Fattovich G,Farci P,Rugge M, etal. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology,1992,15(4):584-589.
[107]Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatmen of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology, 2001,121(1):101-109.
[108]Amarapurkar DN,Patel ND. Combination of peginterferon Alpha-2b(12kD) and lamivudine in difficult-to-treat chronic hepatitis B an Indian experience[J]. Ann Hepatol,2005,4(1):56-59.
[109]Cooksley WG, Piratvisuth T, LeeSD, etal. Peginterferon alpha-2a(40kDa):an advance in the treatment of hepatitis B e antigen-positive Chronic hepatitis B. J Viral Hepat,2003,10(4):298-305.
[110]Lok AS, Lai CL, Leung N,et al.Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology,2003,125(6):1714-1722.
[111]Dienstag JL, Goldin RD, Heathcote EJ, etal. Histological outcome duringlong term lamivudine therapy. Gastroenterology,2003,124(1):105-117.
[112]Liaw YF, Sung JJ, Chow WC, etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med,2004,351(15):1521-1531.
[113]Hann HW, Fontana RJ, Wright T, et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl,2003,9(1):49-56.
[114]Figlerowicz M, Kowala-Piaskowska A, Filipowicz M, et al. Efficacy of lamivudine inthe treatment of children with chronic hepatitis B. Hepatol Res,2005, 31 (4):217-222.
[115]姚光弼,王宝恩,崔振宇,等.拉米夫定治疗慢性乙型肝炎三年疗效观察.中华内科杂志,2003,42(6)：382-387.
[116]姚光弼,崔振宇,姚集鲁,等.国产拉米夫定治疗2200例慢性乙型肝炎的Ⅳ期临床试验.中华肝脏病杂志,2003,11(2)：103-108.
[117]Marcellin P, Chang TT, Lim SG, et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med,2003,348(9): 808-816.
[118]Minde Z, Yimin M, Guangbi Y, et al. A double blind randomized trial of adefovir dipivoxil in Chinese subjects with HbeAg positive chronic hepatitis B[J]. Hepatology,2006,43(1):108-116.
[119]陆宁,徐园.阿德福韦酯联合苦参素治疗YMDD变异慢性乙型肝炎患者的疗效.中国医院药学杂志,2008,28(17)：1484-1486.
[120]Peters MG, Hann HwH, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine resistant chronic hepatitis B. Gastroenterology,2004,126(1):91-101.
[121]Perrillo R,Hann HW, Mutimer D, et al.Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology,2004,126(1):81-90.
[122]吴锦瑜,黎明,郎梅春.阿德福韦酯治疗YMDD变异的乙型肝炎肝硬化患者近期疗效观察.肝脏,2006,11(3)：215-216.
[123]Qi X, Snow A, Thibault V, et al, Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy. J Hepatol,2004,40(suppl1):20-21.
[124]Izzedine H, Hulot JS, Launay Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B:two double-blind, randomized, placebo-controlled studies. Kidney Int,2004,66(3):1153-1158.
[125]Colonno, RJ, Genovesi EV, Medina I, et al. Long-term entecavir treatment result in sustained antiviral efficacy and prolonged life span in the wood chuck model of chronic hepatitis in fection[J].J Infect Dis,2001,184(10):1236-1245.
[126]Marion PL, Salazar FH, Winters MA, et al. Potent efficacy of entecavir(Bms-200475) in a duck model of hepatitis B virus replication[J]. Antimicrob Agents Chemother,2002,46(1):82-88.
[127]Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology,2002,123(6):1831-1838.
[128]Chang T. Entecavir is superior to Lamivudine for the treatment of HbeAg(+) chronic hepatitis B:results of phase Ⅲ study ETV-022 in nucleoside-naive patients [J].Hepatology,2004,40(4Suppl1):193A.
[129]姚光弼,任红,王宝恩,等.恩替卡韦治疗拉米夫定失效的慢性乙型肝炎患者多中心随机双盲对照临床研究.肝脏,2005,10(1)：2-4.
[130]Schiff ER. Entecavir 1. Omg is consistentently superior to lamivudine at 48 weeks across multiple baseline HBV disease characteristics in lamivudine refractory patients[J]. Hepatology,2004,40(4suppll):131
[131]Colonno RJ, Rose R, Levine SM, et al. Emergence of entecavir resistant hepatitis B virus after one year of therapy in phase II&III studies is only observed in lamivudine refractory patients. Hepatology,2004,40(4suppll):661A.
[132]Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis R e antigen-positive chronic hepatitis B. Gastroenterology,2005,129 (2):528-536.
[133]Lai CL, Gane E, Hsu CW, et al. Two-Year Results from the GLOBE Trial in Patients with Hepatitis B:Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine. Hepatology,2006,41 (4 Suppl1):222A.
[l34]Bzowej N, Chan LYH, Lai CL, et al. A randomized trial of telbivudine(LdT) vs. adefovir for HBeAg-positive chronic hepatitis B:final week 52 results. Hepatology,2006,44(4Suppl 1):563A.
[135]LAU G, COOKSLEY H, RIBEIRO R M, et al. Double-blind study comparing adefovir dipivoxil (ADV)plus emtricitabine(Frc) combination therapy versus ADV alone in HBeAg+chronic hepatitis B:Efficacy and mechanisms of treatment response [J]. Hepatology,2004,40(4Suppl1):272A.
[136]DANDO T M,WAGSTAFF A J.Emtrieitabine/tenofovir disoproxil fumarate[J]. Drugs, 2004,64(18):2075-2082.
[137]STEVENS RC, BLUM MR, ROUSSEAU FS, etal. Intracel lular pharmacology of emtricitabine and tenofovir[J]. Clin Infect Dis,2004,15(6):877-878.
[138]Gish RG,Trinh H,Leung N, et al. Safety and antiviral ativity of emtricitabine(FTC) for the treatment of chronic hepatitis B infection:a two-year study [J]. J Hepatol,2005,43 (1):60-66.
[139]Marcellin P, Mommeja-Marin H, Sacks SL,et al. A phase Ⅱ dose escalatine trial of clevudine in patients with chronic hepatitis B[J]. Hepatology,2004,40(1):140-148.
[140]Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofowir in HIV-1 and hepatitis B virus co-infected individual[J]. AIDS,2003,17(1):F7-10.
[141]Van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine resistant hepatitis B virus(HBV)infection[J].Hepatology,2004,40(6):1421-5.
142]刘秦.抗乙肝药物ACH-126443[J].药学进展,2004,28(3)：140.
[143]吴荻,牛俊奇,吴新宇,等.一种新型MCC-478衍生物抗乙型肝炎病毒活性及体外毒性实验.吉林大学学报(医学版),2007,33(3)：422-426.
[144]Chao-Pin Li,Li-Fa Xu,Chao Zhang,etal.Extraction of protoporphyrin disodium and its inhibitory effects on HBV-DNA.World J Gastroenterol,2004,10(3):433-6.
[145]范巧云,刘群红,李朝品,等.原卟啉钠的制备及其体外抗乙型肝炎病毒作用的实验性研究.陕西医学杂志,2006,35(11)：1443-1445.
[146]雷延昌,马涛,郝友华,等.载脂蛋白质B mRNA编辑酶催化多肤3G抑制乙型肝炎病毒和鸭乙型肝炎病毒复制.中华肝脏病杂志,2006,14(10)：738-741.
[147]李声方,方兮,桂希恩,等.当归多糖对HBV转基因小鼠树突状细胞功能状态的影响.实用诊断与治疗杂志,2005,19(5)：313-314.
[148]Samuel CE.Antiviral actions of interferons[J].Clin Microbiol Rev,2001,14:778-809.
[149]Chee AV,Roizman B. Herpes simplex virus 1 gene products occlude the interferon signaling pathway at multiple sites[J].J Virol,2004,78(8):4185-4196.
[150]张权,魏来,王燕ISGF3:IFN-α抗乙型肝炎病毒信号转导机制的重要因子.中华实验和临床病毒学杂志,2005,19(2)：110-113.
[151]盛国光,黄腊平,晏雪生,等.海珠益肝胶囊胶囊对HepG2.2.15细胞Fas、Bax、bcl-2的影响.实用肝脏病杂志,2003,6(2)：70-72.
[152]李莉,唐冲华,余光开,等.抑毒调平液对Th 1/Th2细胞平衡的调节及其抗乙型肝炎病毒活性的研究.中华肝脏病杂志,2003,11(4)：247
[153]Li SF,Wang X,Gui XE,et al.Effects of angelica polysaccharide on the functional status of dendritic cells in HBC trans-genic mice[J].J Pract Diang Ther,2005,19(5):313-315.
[154]张红栓,杨运高,华何与,等.乙肝扶正排毒胶囊体外抗乙肝病毒及对NF-kb活化干预的实验研究.湖南中医杂志,2006,22(3)：84-86
[155]Levent G, Ali A, Ahmet A, Polat EC, Aytac C, Ayse E, Ahmet S. Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy. J Transl Med 2006,4:25.
[156]Dikici I, Mehmetoglu I, Dikici N,etal. Investigation of oxidative stress and some antioxidants in patients with acute and chronic viral hepatitis B and the effect of interferon-alpha treatment. Clin Biochem,2005,38(12):1141-1144.
[157]Piccoli C, Scrima R, Quarato G, etal.Hepatitis C virus protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-oxidative stress. Hepatology 2007,46(1):58-65
[158]McClain SL, Clippinger AJ, Lizzano R, etal. Hepatitis B virus replication is associated with an HBx-dependent mitochondrion-regulated increase in cytosolic calcium levels. J Virol 2007,81(21):12061-12065.
[159]Zhang W, Cox AG, Taylor EW. Hepatitis C virus encodes a selenium-dependent glutathione peroxidase gene. Implications for oxidative stress as a risk factor in progression to hepatocellular carcinoma. Med Klin (Munich),1999,94 (Suppl 3):2-6.
[160]Jiang B F, Xu X F, Li L,et al. Study on"911"Anti-HBVEffect in Hep G2.2.215 cells culture [J].Modern Prev Med,2003,30(4):517.
[161]扶云碧,张广森BCR/ABL癌基因启动JAK/STAT信号转导途径的机制后果及意义.外医学输血及血液学分册,2001,24(6)：473-475.
[162]毛国强,许红梅,朱朝敏.MxA蛋白研究进展[J].国外医学病毒学分册,2005,12：107-110.
[163]管世鹤,杨东亮,陆蒙吉.干扰素抗病毒蛋白MxA和2',5'-OAS在肝胚瘤细胞株中的差异表达.中国感染与化疗杂志,2006,6(3)：149-153
[164]Spudich A, Frigg R, Kilic E, et al. Aggravation of ischemic brain injury by prion protein deficiency:role of ERK-1/-2 andSTAT-1 [J]. Neurobiol Dis,2005,20(2):442-449.
[165]杨馨,李继书,杨慎峭,等.艾灸对实验性类风湿性关节炎家兔滑膜细胞JAK/STAT信号通路影响的研究.针刺研究,2007,32(2)：75-79.
[166]王松柏,孙家潭JAK/STAT通路对脓毒症大鼠肝组织IL-10表达的影响.张家口医学院学报,2003,20(4)：14-16.
[167]沈诚,范士志,陈建明,等JAK/STAT通路对缺血再灌注心肌NF-κB和Caspase-3表达的影响.中国误诊学杂志,2006,6(1)：6-8.
[168]周凤桐,陶国才,王松柏,等.感染性休克大鼠JAK/STAT对组织IFN-Y表达的影响.第三军医大学学报,2006,28(15)：1585-1587.
[169]张芸,赵中夫,韩德五,等.雷帕霉素抑制JAK/STAT通路对急性肝损伤大鼠肝组织HMGB1表达的影响.世界华人消化杂志,14(19)：1916-1920.
[170]郑敏,卢葵花,吴基良,等.大蒜多糖体外抗乙型肝炎病毒作用研究.中药药理与临床2005,21(3)：29-30.
[171]鲁小杰,黄正明,杨新波,等.金丝桃苷对鸭HBV感染的保肝作用.中药药理与临床2007,23(2)：10-12.
[172]徐庆,宋芸娟,李丽亚,等.荔枝核总黄酮的抗鸭乙型肝炎病毒作用.世界华人消化杂志2005,13(17)：2082-2085.
[173]刘中景,熊曼琪,张洪来.小柴胡汤抗鸭乙肝病毒的实验研究.中国中西医结合杂志,2000,20(11)：853-855.
[174]Sells M A. Production of hepatitis B virus particles in HepG2 cells transfected witll cloned hepatitis B virus DNA[J]. Proc Nail Acad Sci USA,1987,84(4):1005-1009.
[175]Sells MA,Zelent AZ,Shvartsman M,etal.Replicative intermediates of hepatitis Bvirus in HepG2 cells that produce infectious virions.J Virol,1988,62(8):2836-2844.
[176]徐陈槐,刘克洲,何南祥,等.鸭乙型肝炎动物模型的建立和DHBV在肝脏的定位研究[J].中国人兽共患病杂志,1994,10(6)：2-5.
[177]Kundgen LR,Thoma C,Kock J,etal.Inhibition of duck hepatitis Bvirus replication by intrahepatic expression of an antiviral resistance gene[J].JMolMed,2002,80(3):187-195.
[178]朱清静,聂广,李翰旻,等.鸭乙型肝炎肝纤维化模型的研究[J].临床与实验病理学杂志,2000,16(6)：501-502.
[179]Breiner KM,Urban S,Glass B,etal.Envelope protein-mediated down-regulation of hepatitis B virus receptor in infected hepatocytes.JVirol,2001,75(1):143-150.
[180]Urban S.Binding of duck carboxypeptidase D to duck hepatitis B virus.Methods MolMed,2004,95:199-212.
[181]陈压西,郭树华,齐珍元,等.叶下珠有效部位抗鸭乙型肝炎病毒及体外抗HBV活性的研究.中药药理与临床,1999,15(6)：16-18
[182]彭立生,贺劲松,童光东,等.叶下珠提取物抗乙肝病毒及乙肝病毒X基因的研究.中西医结合肝病杂志,2006,16(6)：340-340.
[183]李向荣,陈琳,郭靖,等.叶下珠对HBVM的影响100例报告.实用新医学,2001,3(1)：39.
[184]周军,李茂,樊亦军.叶下珠醇提物对实验性肝损伤的保护作用.广西中医学院学报,2004,7(1)：5-7.
[185]冯天保,田广俊,李华,等.福建叶下珠抗小鼠免疫性肝损伤的实验研究.中药新药与临床药理,2005,16(3)：343-345.
[186]蔡树华,蒋如华.叶下珠对小鼠酒精性肝损伤的保护作用.实用肝脏病杂志,2007,10(1)：19-21.
[187]侯周华,谭德明.苦参碱治疗慢性乙型肝炎的临床研究[J].实用预防医学,2005,12(4)：824-826.
[188]王啸,董香玉,朱传安.苦参素对慢性乙型肝炎外周血T淋巴细胞亚群的影响[J].临床荟萃,2001,16(18)：841.
[189]赵洪莹.苦参素注射液治疗慢性乙型肝炎后肝纤维化的疗效[J].中华腹部疾病杂志,2005,5(6)：449-450.
[190]孙其山,丁蔚芋,李亚峰.肝苏颗粒治疗病毒性肝炎386例[J].中西医结合肝病杂志,2001,11(6)：355-356.
[1]李卫强,朱西杰.常占杰治疗慢性乙型肝炎经验.辽宁中医杂志,2007,34(7)：879-880.
[2]张红栓,杨运高,华何与,等.乙肝扶正排毒胶囊体外抗HBV及对NF-kB活化干预的实验研究.湖南中医杂志,2006,22(3)：84-86.
[3]刘丽丽,李常青,朱宇同,等.清肝排毒饮抗鸭乙型肝炎病毒的实验研究.中国热带医学,2007,7(2)：193-195.
[4]陈诗慧,莫运涛.疏肝健脾祛湿中药体内抗鸭乙型肝炎病毒的实验研究.中国医药导报,2008,5(13)：25-26.
[5]邱杰文,黄彩华,程红球,等.黄萱益肝散抗鸭乙型肝炎病毒及保护肝细胞的实验研究.现代中西医结合杂志,2008,17(14)：2128-2129.
[6]刘汉平,何金洋,梁波.扶正利湿活血复方对鸭胚肝细胞中鸭乙型肝炎病毒的抑制作用.时珍国医国药,2009,20(7)：1670-1672..
[7]李顺天,梁树人,李秀梅,等.戴茵兰益肝颗粒剂体外抑制乙型肝炎病毒复制的实验研究.天津中医药,2007,24(3)：236-237.
[8]党双锁,陈云茹,程延安,等.黄芪蛰虫合剂体外抗乙型肝炎病毒的作用观察.第四军医大学学报,2006,27(20)：1840-1842。
[9]林兴,黄权芳,张士军,等.六月青含药血清对HepG2.2.15细胞系HBsAg与HBeAg表达的影响.时珍国医国药,2009,2(7)：1603-1604.
[10]张士军,林兴,林军,等.复方六月雪含药血清对2.2.15细胞和的抑制作用.中成药,2007,29(6)：805-809.
[11]谭行华,王建,吴茂盛,等.愈肝胶囊对2.2.15细胞分泌HBsAg!HBeAg的抑制作用.中西医结合肝病杂志,2004,14(3)：158-160.
[12]谭行华,张爱民,余卫华,等.愈肝胶囊的抗鸭HBV作用研究.中药材,2005,28(8)：679-681.
[13]刘春荣,许小林,薛强,等.复方鬼辣椒根液对鸭乙型肝炎治疗作用的研究.右江医学,2007,35(3)：292-293.
[14]徐颖,黄正明,徐必学,等.苯丙氨酸二肽类化合物073对2.2.15细胞分泌HBsAg和HBeAg的影响.解放军药学学报,2009,25(2)：120-124.
[15]唐庆年,冯梅,龚受基,等.雪灵芝提取物对HepG2.2.15细胞株HBsAg与HBeAg表达的影响.中药材,2008,31(8)：1212-1215.
[16]Jiyang Li,HaiHuang,MeiqingFeng,etal.In vitro and in vivo anti-hepatitis B virus activities of a plant extract from Geranium carolinianum L. Antiviral Research,2008,79:114-12.
[17]Y.-L.Zhao,G.-M.Cai,X.Hong,etal.Anti-hepatitis B virus activities of triterpenoid saponin compoundfrom Potentilla anserine L. Phytomedicine,2008,15:253-258.
[18]杨柯,郑作文,欧贤红.广西藤茶提取物TTF含药血清对乙型肝炎病毒HBsAg和HBeAg的抑制作用.医药导报,2008,27(4)：390-392.
[19]杨柯,郑作文.广西藤茶提取物TTF抗鸭乙型肝炎病毒的实验研究.时珍国医国药,2007,18(11)：2634-2635.
[20]万新祥,张鑫,刘强,等.皱瘤海鞘体外抗HBV作用的初步研究.第一军医大学分校学报,2002,25(2)：84-85.
[21]李春荣,林晓春,陈广辉,等.皱瘤海鞘正丁醇部位体外抗HBV的初步研究.时珍国医国药,2007,18(9)：2116.
[22]李宝剑,金丽琴,左江成.细脚拟青霉多糖抗乙型肝炎病毒的体外实验研.中药材,2007,30(2)：200-203.
[23]黄华,王歆君,杨巧丽,等.布亚胶囊抗HBV作用的试验研究.新疆中医药,2009,27(4)：3-5.
[24]湛孝东,王克霞,李朝品.蜗牛多糖体外抗乙型肝炎病毒作用研究.中国实验方剂学杂志.2008,14(3)：66-68.
[25]刘妮,肖会泉,沈海容,等.小叶榕水提物对]HBsAg和HBeAg体外抑制作用的实验研究.浙江中西医结合杂志,2009,19(8)：486-490.
[26]谢琼,谭德明,彭忠田,等.脱氧野尻霉素抑制乙型肝炎病毒复制的体外实验研究.中国感染控制杂志,2009,8(1)：3-6.
[27]李永伟,郭云蔚,李刚,等.甘草甜素对HepG2.2.15细胞株HBV感染的影响.中国中医药信息杂志,2009,16(9)：31-33.
[28]饶敏,张淑玲,董继华,等.高三尖杉酯碱等四种药物的体外抑制HBV的实验研究.中国病毒学,2006,21(3)：284-287.
[29]吴晓蔓,袁文声.黄芪抗乙型肝炎病毒的体外实验研究.广东医学,2008,29(1)：37-38.
[30]陆伦根,曾民德,茅益民,等.氧化苦参碱治疗慢性乙型肝炎的随机双盲对照多中心研究.中华肝脏病杂志,2004,12(10)：597-600.
[31]平键,成扬,许怀栋,等.氧化苦参碱黄芩苷组合物抗乙型肝炎病毒和抗肝纤维化的体外实验.实用脏病杂志,2007,10(3)：148-151.
[32]吴荻,牛俊奇,吴新宇,等.一种新型MCC-478衍生物抗乙型肝炎病毒活性及体外毒性实验.吉林大学学报(医学版),2007,33(3)：422-426.
[33]蔡钦生,冯美卿,黄海,等.阿昔洛韦棕榈酰酯的高效合成!结构表征及其体外抗HBV的 作用.复旦学报(医学版),2007,34(4)：468-472.
[34]Chao-Pin Li,Li-Fa Xu,Chao Zhang,etal.Extraction of protoporphyrin disodium and its inhibitory effects on HBV-DNA.World J Gastroenterol,2004,10(3):433.
[35]范巧云,刘群红,李朝品,等.原卟啉钠的制备及其体外抗乙型肝炎病毒作用的实验性研究.陕西医学杂志,2006,35(11)：1443-1445.
[36]孟斌,温博贵,韩金祥.丁型肝炎病毒核酶的结构特点与催化作用机制.中国生物工程杂志,2003,23(8)：52-56.
[37]戚鹏,韩金祥,鲁艳芹,等.逆转录病毒靶向介导HDV核酶体外抑制HBV表达.中国生物制品学杂志,2007,20(4)：233-236.
[38]Oka Y,Akbar SM,Horiike N,etal.Mechanism and therapeutic potential of DNA-based immunization against the envelope proteins of hepatitis B virus in normal and transgenic mice[J].Immunology,2001,103(1):90-97.
[39]杨富强,陈光明,何晓嫱,等HBVDNA疫苗诱导健康及HBV转基因小鼠细胞免疫应答.解放军医学杂志,2003,28(6)：501-503.
[40]Harris RS, Bishop KN, Sheehy AM, et al. DNA deamination mediates innate immunity to retroviral infection. Cell,2003,113:803-809.
[41]雷延昌,马涛,郝友华,等.载脂蛋白质B mRNA编辑酶催化多肤3G抑制乙型肝炎病毒和鸭乙型肝炎病毒复制.中华肝脏病杂志,2006,14(10)：738-741.